Vanguard Global Advisers
RXRX icon

Vanguard Global Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Vanguard Global Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759K Sell
206,759
-40
-0% -$133 ﹤0.01% 1907
2026
Q1 		$635K Buy
+206,799
New +$799K ﹤0.01% 1927

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Global Advisers's RXRX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Recursion Pharmaceuticals (RXRX) stake by 0.02% in Q2 2026, selling an estimated $133 and leaving 206,759 shares worth $759K. The position accounts for ﹤0.01% of the portfolio, ranked #1907.

Vanguard Global Advisers first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 338 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Vanguard Global Advisers held 206,759 shares of Recursion Pharmaceuticals worth $759K as of Q2 2026.
  • Vanguard Global Advisers sold 40 Recursion Pharmaceuticals shares in Q2 2026, an estimated $133.
  • Recursion Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1907 holding.
  • Vanguard Global Advisers first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 338 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.